Dr. Jeffrey Goldstein, MD
Claim this profileSt. John's Hospital (Prairie)
Studies Mitral Valve Regurgitation
Studies Heart Valve Disease
9 reported clinical trials
22 drugs studied
Affiliated Hospitals
Clinical Trials Jeffrey Goldstein, MD is currently running
Mitral Valve Repair vs. MitraClip Implantation
for Mitral Valve Regurgitation
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Recruiting1 award N/A6 criteria
Tendyne Transcatheter Mitral Valve System
for Mitral Regurgitation
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification. This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and are also not suitable for transcatheter repair with MitraClip, will be enrolled in the Non-repairable cohort. Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.
Recruiting1 award N/A4 criteria
More about Jeffrey Goldstein, MD
Clinical Trial Related3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Jeffrey Goldstein, MD has experience with
- ACURATE Neo2™ Transfemoral TAVR System
- Medtronic CoreValve TAVR System
- Edwards SAPIEN 3 TAVR System
- ACURATE Prime™ Transfemoral TAVR System XL
- Tendyne Mitral Valve System
- MitraClip System
Breakdown of trials Jeffrey Goldstein, MD has run
Mitral Valve Regurgitation
Heart Valve Disease
Cardiovascular Disease
Mitral Regurgitation
Lumbar Spine Degeneration
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeffrey Goldstein, MD specialize in?
Jeffrey Goldstein, MD focuses on Mitral Valve Regurgitation and Heart Valve Disease. In particular, much of their work with Mitral Valve Regurgitation has involved Stage III patients, or patients who are undergoing treatment.
Is Jeffrey Goldstein, MD currently recruiting for clinical trials?
Yes, Jeffrey Goldstein, MD is currently recruiting for 3 clinical trials in Springfield Illinois. If you're interested in participating, you should apply.
Are there any treatments that Jeffrey Goldstein, MD has studied deeply?
Yes, Jeffrey Goldstein, MD has studied treatments such as ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System, Edwards SAPIEN 3 TAVR System.
What is the best way to schedule an appointment with Jeffrey Goldstein, MD?
Apply for one of the trials that Jeffrey Goldstein, MD is conducting.
What is the office address of Jeffrey Goldstein, MD?
The office of Jeffrey Goldstein, MD is located at: St. John's Hospital (Prairie), Springfield, Illinois 62769 United States. This is the address for their practice at the St. John's Hospital (Prairie).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.